(Q40318288)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Paolo Rebulla

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Stefania Vaglio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Francesco Beccaria

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Angelo Carella

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Federico Chiurazzi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Serelina Coluzzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Agostino Cortelezzi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Giorgio Gandini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Gabriella Girelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Maria Graf

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Paola Isernia

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Giuseppe Marano

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Maurizio Marconi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Rachele Montemezzi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Barbara Olivero

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Marianna Rinaldi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Laura Salvaneschi

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Nicola Scarpato

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Paolo Strada

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Silvano Milani

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Giuliano Grazzini

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

24 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

1171-1183

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

Component pathogen inactivation: a critical review

3 April 2020

cites work

1 reference

Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands

21 January 2018

1 reference

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

21 January 2018

1 reference

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

21 January 2018

1 reference

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

21 January 2018

1 reference

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

21 January 2018

1 reference

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

21 January 2018

1 reference

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

21 January 2018

1 reference

A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.

21 January 2018

1 reference

Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period

21 January 2018

1 reference

The safety of the blood supply--time to raise the bar.

21 January 2018

1 reference

Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance

21 January 2018

1 reference

Zika virus: following the path of dengue and chikungunya?

21 January 2018

1 reference

Health economics and outcomes methods in risk-based decision-making for blood safety

21 January 2018

1 reference

Reporting results of cancer treatment

21 January 2018

1 reference

Dose of prophylactic platelet transfusions and prevention of hemorrhage

21 January 2018

1 reference

21 January 2018

1 reference

Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations

21 January 2018

1 reference

Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets

21 January 2018

1 reference

Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system

21 January 2018

1 reference

Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

21 January 2018

1 reference

Modeling the risk of an emerging pathogen entering the Canadian blood supply

21 January 2018

1 reference

The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model

21 January 2018

1 reference

Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates.

21 January 2018

1 reference

Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.

21 January 2018

1 reference

Reducing the financial impact of pathogen inactivation technology for platelet components: our experience

21 January 2018

1 reference

Cost implications of implementation of pathogen-inactivated platelets

21 January 2018

1 reference

Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis

21 January 2018

1 reference

Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood products

21 January 2018

1 reference

Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

21 January 2018

1 reference

Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial

21 January 2018

1 reference

When is the 'right' time to initiate an assessment of a health technology?

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/TRF.14042

Identifiers

DOI

10.1111/TRF.14042

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28236335%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference